Press release
With over 20 approved products and several more in the pipeline, the HUMIRA® biosimilars market is projected to witness considerable growth over the coming years, claims Roots Analysis
Unlike other biosimilar markets, competition among follow-on products of HUMIRA® is very high and several eager companies are attempting to carve out a share of the multibillion-dollar opportunity associated with this blockbuster productRoots Analysis has announced the addition of the “HUMIRA® (Adalimumab) Biosimilars – Pipeline Review and Partnerships” report to its list of offerings.
Being one of the first biologics against anti-inflammatory diseases, HUMIRA® is considered an aberration in terms of patent protection, with AbbVie strategically covering novel uses of the product and thereby, enjoys uncharacteristically prolonged marketing exclusivity. In fact, a year after multiple adalimumab biosimilars were launched in Europe, the originator released a statement that its diverse product placement strategy was able to maintain profitability, despite the availability of enemy products.
To order this report, which features 50+ insightful figures, depicting key analytical takeaways, please visit this link - https://www.rootsanalysis.com/reports/humira-biosimilars-pipeline-review-and-partnerships.html
Key Report Highlights
Despite direct competition from marketed biosimilars, global sales of the blockbuster drug, HUMIRA® increased by 4% in 2020
In the same year, revenues from the sales of the originator product were reported to be responsible for 30% of AbbVie’s earnings from product sales; it is worth mentioning that this is the scenario almost two years after the regulated launch of follow-on products in Europe.
There are close to 50 companies, across the world, claiming to be engaged in the development of HUMIRA® biosimilars
Although multiple companies have obtained regulatory approvals for their respective biosimilars to HUMIRA®, the launch of these products in regulated markets has been delayed until 2023 and is subject to the procurement of the appropriate licenses from AbbVie.
Multiple adalimumab biosimilar candidates are presently under development across more than 70 trials, worldwide
For several such investigational leads, new drug applications (NDAs) / marketing authorization applications (MAAs) have already been submitted to regulators across the world.
Partnership activity, related to biosimilars of adalimumab, has grown at a gradual pace since 2012
Most of the deals reported in the public domain are licensing and commercialization agreements; this trend can be attributed to the fact that biosimilar developers generally tend to partner with local business entities in order to launch their proprietary offerings across different geographies.
To request a sample copy / brochure of this report, please visit this link - https://www.rootsanalysis.com/reports/humira-biosimilars-pipeline-review-and-partnerships.html
Key Questions Answered
Who are the key players engaged in the development of biosimilars of adalimumab?
In which global marketplaces are HUMIRA® biosimilars currently available?
What is the current scenario within the clinical development landscape of adalimumab biosimilars?
How many biosimilar development programs have and what were the reasons?
Who are the key players involved in the commercialization of adalimumab biosimilars across the world?
What kind of partnerships have been inked between stakeholders in this domain?
The research includes detailed profiles of companies having approved / launched biosimilars across different global regions; each profile features an overview of the company, information related to its current portfolio of adalimumab biosimilars, financial information (if available) and key product related specifications.
Amgen
Bio-Thera Solutions
Boehringer Inglheim
Cadila
Celltrion
CinnaGen
Cipla
Emcure
Fresenius Kabi
Fujifilm Kyowa Kirin Biologics
Hetero Biopharma
Hetero Healthcare
Innovent Biologics
LG Chem (formerly LG Life Sciences)
Pfizer
Reliance Life Sciences
Samsung Bioepis
Sandoz
Shanghai Henlius Biotech
Torrent Pharmaceuticals
Zydus Cadila
Zydus Research Centre
For additional details, please visit
https://www.rootsanalysis.com/reports/humira-biosimilars-pipeline-review-and-partnerships.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships
2. Herceptin® (Trastuzumab) Biosimilars – Pipeline Review and Partnerships
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release With over 20 approved products and several more in the pipeline, the HUMIRA® biosimilars market is projected to witness considerable growth over the coming years, claims Roots Analysis here
News-ID: 2401987 • Views: …
More Releases from Roots Analysis

Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Prot …
According to our latest market report "Proteomics Market" by Type of Offering, Type of Instrument / Technology, Type of Reagent, Type of Proteomics Service, Application Area, End-users, Type of Operation and Geography: Industry Trends and Global Forecasts, Till 2035", the global protein expression market, valued at USD 2.7 billion in 2024, is estimated to reach USD 3.0 billion in 2025 and USD 6.3 billion by 2035, representing a CAGR of…

Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising …
09-04-2025 | Robotics & Automation
Press release from: Roots Analysis
According to Roots Analysis' latest industry report titled "Industrial Robotics Market: Industry Trends and Global Forecasts, till 2035", the global industrial robotics market is projected to grow from USD 17.64 billion in 2024 to USD 18.80 billion in 2025, reaching USD 39.03 billion by 2035 at a CAGR of 7.5% during the forecast period.
To request a quote for this report, visit:
https://www.rootsanalysis.com/industrial-robotics-market/request-quote
Market Overview
Industrial…

Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | R …
According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till…

The Conjugation and Labeling Services Market is projected to grow at a CAGR of 1 …
The complexities associated with conjugation of biomolecules and the need for click-chemistry expertise have prompted the pharmaceutical industry to rely on conjugation and labeling service providers
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market/request-quote.html
Roots Analysis is pleased to announce the publication of its recent study, titled, "Conjugation and Labeling Services Market, 2023-2035"
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.…
More Releases for HUMIRA®
Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug: The Drivi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Humira Drug Market Size Growth Forecast: What to Expect by 2025?
The market size for the Humira drug has been experiencing robust growth in the past few years. It is projected to expand from $9.74 billion in 2024 to $10.43 billion in 2025, at a compound annual growth rate…
Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug: A Key Dri …
The Humira Drug Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Humira Drug Market Size and Its Estimated Growth Rate?
In recent times, the Humira drug market has witnessed robust growth. This upward trajectory is expected to continue, with predictions estimating a…
Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug: A Key Dri …
The Humira Drug Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Humira Drug Market Size and Its Estimated Growth Rate?
In recent times, the Humira drug market has witnessed robust growth. This upward trajectory is expected to continue, with predictions estimating a…
Prominent Humira Drug Market Trend for 2025: Innovative Formulations Drive Advan …
Which drivers are expected to have the greatest impact on the over the humira drug market's growth?
The upsurge in the occurrence rate of autoimmune diseases is predicted to bolster the expansion of the Humira drug market in the future. Autoimmune diseases denote conditions where the immune system of the body mistakenly attacks and destroys healthy cells and tissues. The Humira drug is utilized to alleviate pain and inflammation stemming from…
Evolving Biologics: Humira Drug Market Dynamics for 2024
"The Business Research Company recently released a comprehensive report on the Global Humira Drug Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Humira Market 2023 | Detailed Report
The Humira research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses, significant market key players are also enlisted in order to deliver readers with in-depth analysis about industry strategies.
The Humira report…